Proteomics profiling of inflammatory responses to elexacaftor/tezacaftor/ivacaftor in cystic fibrosis

BackgroundCFTR modulator therapies have positive clinical outcomes, yet chronic inflammation and bacterial infections persist in people with CF (pwCF). How elexacaftor–tezacaftor–ivacaftor (ETI) fails to improve innate immune signaling responsible for bacterial clearance and inflammation resolution...

书目详细资料
发表在:	Frontiers in Immunology
Main Authors:	Hazel Ozuna, Dinesh Bojja, Santiago Partida-Sanchez, Luanne Hall-Stoodley, Amal Amer, Rodney D. Britt, Shahid Sheikh, David A. Frank, Weiyuan Wang, Bum-Yong Kang, Irina Miralda, Samantha L. Durfey, Benjamin T. Kopp
格式:	文件
语言:	英语
出版:	Frontiers Media S.A. 2025-01-01
主题:	cystic fibrosis inflammation proteomics modulators NF-κB
在线阅读:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1486784/full

相似书籍

Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis: a systematic review and economic evaluation
由: Steven J Edwards, et al.
出版: (2025-05-01)

Impact of elexacaftor/tezacaftor/ivacaftor on the small airways in cystic fibrosis
由: Sofia Campos Silva, et al.
出版: (2025-06-01)

Impact of elexacaftor/tezacaftor/ivacaftor on depression and anxiety in cystic fibrosis
由: Lijia Zhang, et al.
出版: (2022-12-01)

Post-approval studies with the CFTR modulators Elexacaftor-Tezacaftor—Ivacaftor
由: Burkhard Tümmler, et al.
出版: (2023-03-01)

Cystic fibrosis: desensitization in delayed hypersensitivity reactions to elexacaftor/tezacaftor/ivacaftor
由: L. Gómez-Ganda, et al.
出版: (2024-06-01)

Effect of elexacaftor–tezacaftor–ivacaftor modulator on lung structure in cystic fibrosis
由: V. Fainardi, et al.
出版: (2023-09-01)

Elexacaftor/Tezacaftor/Ivacaftor Population Pharmacokinetics in Pediatric Patients With Cystic Fibrosis
由: Ngoc Hoa Truong, et al.
出版: (2025-05-01)

Cystic fibrosis liver disease progression in the era of elexacaftor–tezacaftor–ivacaftor
由: Charlotte Mouliade, et al.
出版: (2025-10-01)

Cystic fibrosis: new challenges and perspectives beyond elexacaftor/tezacaftor/ivacaftor
由: Vito Terlizzi, et al.
出版: (2025-03-01)

Condition-dependent effects of Elexacaftor/Tezacaftor/Ivacaftor (Trikafta) on Aspergillus fumigatus growth
由: Elise Biquand, et al.
出版: (2025-09-01)

Unveiling the psychosocial impact of Elexacaftor/Tezacaftor/Ivacaftor therapy in Cystic Fibrosis patients
由: Marta Solís García, et al.
出版: (2025-02-01)

Impact of elexacaftor-tezacaftor-ivacaftor in lung transplantation for cystic fibrosis in the United States
由: Tahuanty A. Pena, MD, MS, et al.
出版: (2025-02-01)

Case Series: Hyperbilirubinemia under elexacaftor/tezacaftor/ivacaftor in the presence of Gilbert’s syndrome
由: Julia Weitzel, et al.
出版: (2024-07-01)

The effect of elexacaftor/tezacaftor/ivacaftor on non-pulmonary symptoms in adults with cystic fibrosis
由: Sarah Allgood, et al.
出版: (2023-09-01)

Effects of elexacaftor/tezacaftor/ivacaftor therapy on mental health of patients with cystic fibrosis
由: Linus Piehler, et al.
出版: (2023-04-01)

Elexacaftor/Tezacaftor/Ivacaftor Efficacy in a Cohort of Italian Patients with CFTR Rare Mutations
由: Francesca Lucca, et al.
出版: (2025-03-01)

Organic Synthesis and Current Understanding of the Mechanisms of CFTR Modulator Drugs Ivacaftor, Tezacaftor, and Elexacaftor
由: Filipa C. Ferreira, et al.
出版: (2024-02-01)

Longitudinal profiling of the intestinal microbiome in children with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor
由: Seth A. Reasoner, et al.
出版: (2024-02-01)

Heterogeneity of weight gain after initiation of Elexacaftor/Tezacaftor/Ivacaftor in people with cystic fibrosis
由: Andrea Gramegna, et al.
出版: (2023-06-01)

Efficacy and Safety of Elexacaftor-Tezacaftor-Ivacaftor in the Treatment of Cystic Fibrosis: A Systematic Review
由: Nikoletta Kapouni, et al.
出版: (2023-03-01)

Immunoreactive Trypsinogen in Infants Born to Women with Cystic Fibrosis Taking Elexacaftor–Tezacaftor–Ivacaftor
由: Payal Patel, et al.
出版: (2023-02-01)

Regulatory T cell enhancement in adults with cystic fibrosis receiving Elexacaftor/Tezacaftor/Ivacaftor therapy
由: Dirk Westhölter, et al.
出版: (2023-02-01)

A real-life study of elexacaftor-tezacaftor-ivacaftor therapy in people with cystic fibrosis in Brazil
由: L.Z. Salomão, et al.
出版: (2023-11-01)

Analysis of Depression and Anxiety Scores Following Initiation of Elexacaftor/Tezacaftor/Ivacaftor in Adults With Cystic Fibrosis
由: Harish Pudukodu, et al.
出版: (2024-09-01)

Disproportionate Rates of Liver Injury in People With Cystic Fibrosis on Elexacaftor/Tezacaftor/Ivacaftor in Queensland, Australia
由: Ellie Johnson, et al.
出版: (2025-01-01)

Acute cholecystitis as an adverse effect of treatment with elexacaftor/tezacaftor/ivacaftor in a patient with cystic fibrosis
由: Carlos Martín de Vicente, et al.
出版: (2024-12-01)

Plasma levels of chemokines decrease during elexacaftor/tezacaftor/ivacaftor therapy in adults with cystic fibrosis
由: Dirk Westhölter, et al.
出版: (2024-01-01)

Longitudinal microbial and molecular dynamics in the cystic fibrosis lung after Elexacaftor–Tezacaftor–Ivacaftor therapy
由: Christian Martin, et al.
出版: (2023-12-01)

Therapeutic Drug Monitoring of Ivacaftor, Lumacaftor, Tezacaftor, and Elexacaftor in Cystic Fibrosis: Where Are We Now?
由: Eva Choong, et al.
出版: (2022-08-01)

Real-world effectiveness of elexacaftor/tezacaftor/ivacaftor on the burden of illness in adolescents and adults with cystic fibrosis
由: Thomas Keens, et al.
出版: (2024-04-01)

Elexacaftor–Tezacaftor–Ivacaftor Therapy for Cystic Fibrosis Patients with The F508del/Unknown Genotype
由: Marika Comegna, et al.
出版: (2021-07-01)

Spirometric and anthropometric improvements in response to elexacaftor/tezacaftor/ivacaftor depending on age and lung disease severity
由: Katharina Schütz, et al.
出版: (2023-07-01)

Clinical efficacy of elexacaftor-tezacaftor-ivacaftor in an adolescent with homozygous G85E cystic fibrosis
由: Elena Stekolchik, et al.
出版: (2022-01-01)

Glycemia and β-cell function before and after elexacaftor/tezacaftor/ivacaftor in youth and adults with cystic fibrosis
由: Christine L. Chan, et al.
出版: (2022-12-01)

Scedosporium infection as a late complication after start of elexacaftor/tezacaftor/ivacaftor: two case reports
由: P van Mourik, MD PhD, et al.
出版: (2025-01-01)

BOS-318 treatment enhances elexacaftor–tezacaftor–ivacaftor-mediated improvements in airway hydration and mucociliary transport
由: Lisa E.J. Douglas, et al.
出版: (2025-02-01)

Evolution of Lung Disease Studied by Computed Tomography in Adults with Cystic Fibrosis Treated with Elexacaftor/Tezacaftor/Ivacaftor
由: Susana Hernández-Muñiz, et al.
出版: (2025-04-01)

Anti-inflammatory effects of elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis heterozygous for F508del
由: Heledd H. Jarosz-Griffiths, et al.
出版: (2024-01-01)

Anti-inflammatory effects of elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis heterozygous for F508del.
由: Heledd H Jarosz-Griffiths, et al.
出版: (2024-01-01)

Cystic fibrosis pathogens persist in the upper respiratory tract following initiation of elexacaftor/tezacaftor/ivacaftor therapy
由: Yasmin Hilliam, et al.
出版: (2024-08-01)